CRIS
Price:
$3.17
Market Cap:
$26.84M
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small mol...[Read more]
Industry
Biotechnology
IPO Date
2000-08-01
Stock Exchange
NASDAQ
Ticker
CRIS
According to Curis, Inc.’s latest financial reports and current stock price. The company's current ROE is -924.75%. This represents a change of -326.81% compared to the average of 407.71% of the last 4 quarters.
The mean historical ROE of Curis, Inc. over the last ten years is -20.30%. The current -924.75% ROE has changed 4.45% with respect to the historical average. Over the past ten years (40 quarters), CRIS's ROE was at its highest in in the June 2024 quarter at 1.70%. The ROE was at its lowest in in the September 2018 quarter at -923.66%.
Average
-20.30%
Median
-77.16%
Minimum
-241.04%
Maximum
724.53%
Discovering the peaks and valleys of Curis, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 132.11%
Maximum Annual ROE = 724.53%
Minimum Annual Increase = -426.04%
Minimum Annual ROE = -241.04%
Year | ROE | Change |
---|---|---|
2023 | -241.04% | 86.01% |
2022 | -129.58% | 132.11% |
2021 | -55.83% | 109.14% |
2020 | -26.69% | -124.60% |
2019 | 108.53% | -85.02% |
2018 | 724.53% | -426.04% |
2017 | -222.22% | 7.65% |
2016 | -206.42% | 125.77% |
2015 | -91.43% | 45.40% |
2014 | -62.88% | 130.53% |
The current ROE of Curis, Inc. (CRIS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-142.15%
5-year avg
-68.92%
10-year avg
-20.30%
Curis, Inc.’s ROE is greater than Aileron Therapeutics, Inc. (-46.89%), greater than Artelo Biosciences, Inc. (-26.25%), greater than Histogen Inc. (-80.69%), greater than Timber Pharmaceuticals, Inc. (-209.49%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Mereo BioPharma Group plc (-69.11%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Leap Therapeutics, Inc. (-116.24%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than PDS Biotechnology Corporation (-139.57%), greater than Adaptimmune Therapeutics plc (-74.84%), greater than Pieris Pharmaceuticals, Inc. (-76.24%), greater than Affimed N.V. (-193.85%), greater than Corvus Pharmaceuticals, Inc. (-167.55%), less than Aptose Biosciences Inc. (1.03%),
Company | ROE | Market cap |
---|---|---|
-46.89% | $47.02M | |
-26.25% | $3.13M | |
-80.69% | $85.44K | |
-209.49% | $1.18M | |
-32.51% | $98.92M | |
-69.11% | $589.54M | |
-88.42% | $188.22M | |
-32.76% | $492.65M | |
-116.24% | $111.51M | |
-22.40% | $1.28B | |
-139.57% | $61.35M | |
-74.84% | $148.11M | |
-76.24% | $17.96M | |
-193.85% | $18.88M | |
-167.55% | $314.86M | |
1.03% | $14.88M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Curis, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Curis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Curis, Inc.'s ROE?
How is the ROE calculated for Curis, Inc. (CRIS)?
What is the highest ROE for Curis, Inc. (CRIS)?
What is the 3-year average ROE for Curis, Inc. (CRIS)?
What is the 5-year average ROE for Curis, Inc. (CRIS)?
How does the current ROE for Curis, Inc. (CRIS) compare to its historical average?